Home › Research › Treatments
Real-World Incidence of Amyloid-Related Imaging Abnormalities Associated with Lecanemab: A Systematic Review and Meta-Analysis
Jeong SY, Poo M, Jang H, Lim J, Ghannam S, Fujita S, Ford JN, Lang M et al.. Research Square, 2026-11-17
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Abstract Background Amyloid-related imaging abnormalities (ARIA), including ARIA-edema or effusion (E) and ARIA-hemorrhage (H), are the most common and important treatment-related adverse event of anti-amyloid-β immunotherapy. Real-world populations and clinical management may differ from randomized controlled trials. This study estimated the real-world incidence of ARIA in lecanemab-treated patients and to compare it by geographic region, MRI protocol, and APOE ε4 carrier status. Methods PubMed and Embase were searched for studies published through April 28, 2026. Real-world lecanemab studies in mild cognitive impairment due to Alzheimer disease or Alzheimer dementia reporting ARIA-E or H were included. The pooled incidences of ARIA and subgroup analyses by geographic region, MRI sequence, MRI magnet strength, and APOE ε4 status were calculated with a random-effects model; pooled ORs by APOE ε4 carrier status were also calculated. Results Twenty-one real-world studies were identified, analyzing data from 4,818 patients. Pooled incidence was 14.5% (95%CI: 11.8–17.7) for any ARIA, 5.5% (95%CI, 3.9–7.7) for ARIA-E, 11.5% (95%CI, 9.0–14.4) for ARIA-H. Symptomatic ARIA and severe ARIA occurred in 2.1% (95%CI, 1.4–3.2) and 1.3% (95%CI, 0.8–2.0), respectively, and isolated ARIA-H in 8.5% (95%CI, 6.5–11.0). The incidence of any ARIA varied by geographic region, the highest in the United States (21.6%) and lowest in Asia (12.9%) ( P =.003). Incidence of ARIA-E differed by MRI field strength ( P <.001), whereas incidence of ARIA-H did not differ by MRI sequence ( P =.09). APOE ε4 homozygotes had higher odds of ARIA-E than heterozygotes (OR,3.1; 95%CI, 1.7–5.7) and noncarriers (OR,3.3; 95%CI, 1.7–6.4) (both P <.001), and higher odds of ARIA-H than noncarriers (OR,2.4; 95% CI, 1.1–4.9; P =.02) but not heterozygotes (OR,1.9; 95% CI, 0.96–3.6; P =.07). Conclusion The real-world incidences of ARIA-E (5.5%) and H (11.5%) were lower than those in the Clarity AD trial (12.6% and 17.3%) and pooled phase 3 trials (9.5% and 17.8%). In real-world settings, incidence varied by geographic region (lowest in Asian cohorts), and MRI protocol, and the risk of ARIA-E increased with APOE ε4 gene dose, supporting standardized MRI surveillance and APOE ε4–informed risk stratification for the safe real-world use of lecanemab.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Jeong, S. Y., Poo, M., Jang, H., Lim, J., Ghannam, S., Fujita, S., et al. (2026). Real-World Incidence of Amyloid-Related Imaging Abnormalities Associated with Lecanemab: A Systematic Review and Meta-Analysis. Research Square. https://doi.org/10.21203/rs.3.rs-11538910/v1
Vancouver
Jeong SY, Poo M, Jang H, Lim J, Ghannam S, Fujita S, et al. Real-World Incidence of Amyloid-Related Imaging Abnormalities Associated with Lecanemab: A Systematic Review and Meta-Analysis. Research Square. 2026. doi:10.21203/rs.3.rs-11538910/v1.
BibTeX
@article{jeong2026-1bf42f79,
author = {Jeong, S. Y. and Poo, M. and Jang, H. and Lim, J. and Ghannam, S. and Fujita, S. and Ford, J. N. and Lang, M. and others},
title = {{Real-World Incidence of Amyloid-Related Imaging Abnormalities Associated with Lecanemab: A Systematic Review and Meta-Analysis}},
journal = {Research Square},
year = {2026},
doi = {10.21203/rs.3.rs-11538910/v1},
url = {https://doi.org/10.21203/rs.3.rs-11538910/v1}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Results Twenty-one real-world studies were identified, analyzing data from 4,818 patients.
- APOE ε4 homozygotes had higher odds of ARIA-E than heterozygotes (OR,3.1; 95%CI, 1.7–5.7) and noncarriers (OR,3.3; 95%CI, 1.7–6.4) (both P <.001), and higher odds of ARIA-H than noncarriers (OR,2.4; 95% CI, 1.1–4.9; P =.02) but not heterozygotes (OR,1.9; 95% CI, 0.96–3.6; P =.07).
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designclinical trial
- Participants4,818
- Effect size14.5%; 5.5%; 11.5%
- Evidence strengthHigh
How this study scored 16/100
Preprint — not yet peer-reviewed. It scored 40 on the same rubric, but non-peer-reviewed sources are capped at 16, so it shows as 16. Scored zero for study design and randomized / blinded because the record does not state it. We have no data on times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 25 of the 62 points we could judge it on, which is 40 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 2 / 10 | Tier 4 — not a peer-reviewed journal (Research Square) |
| Journal's citation record | 0 / 4 | Not a journal article, so the journal's record does not count |
| Study design | 0 / 12 | Design recorded as “clinical trial”, which our rubric does not rank (not stated in the record — scored 0) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 4 / 10 | Preprint — not yet peer-reviewed. Hosted on a preprint server. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 3 / 4 | 4,818 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 25 / 62 | Scored on 12 of 20 parts. We have no data for the rest, so they are left out: 25 of the 62 points we could judge it on is 40 out of 100. |
| Total | 40 / 100 | Capped to 16 because this is not a peer-reviewed article. |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Treatments from nearby years
Also tagged “imaging-abnormalities”
3 studies in the library carry the topic tag “imaging-abnormalities”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 3 tagged studies.